Singapore markets open in 35 minutes

hVIVO plc (CRO.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.14600.0000 (0.00%)
At close: 08:01AM CEST

hVIVO plc

21 Plumbers Row
London E1 1EQ
United Kingdom
44 20 7756 1300

Full-time employees218

Key executives

NameTitlePayExercisedYear born
Dr. Yamin Mohammed Khan Ph.D.CEO & DirectorN/AN/A1969
Mr. Stephen PinkertonCFO & Exec. DirectorN/AN/AN/A
Mr. Andrew CatchpoleChief Scientific OfficerN/AN/AN/A
Dr. Maurice N. Treacy Ph.D.Chief Commercial OfficerN/AN/AN/A
Ms. Teja Marathe-SarvadikarHead of QAN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Corporate governance

hVIVO plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.